DDrare: Database of Drug Development for Rare Diseases

16. クロウ・深瀬症候群　［臨床試験数：10，薬物数：12（DrugBank：6），標的遺伝子数：4，標的パスウェイ数：66］

Searched query = "Crow Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = Cyclophosphamide; Dexamethasone; Fpf 300 (thalidomide); G-csf; Ixazomib; Ixazomib citrate; Lenalidomide; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Revlimid*21cps 25mg; Thalidomide

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02921893	October 31, 2016	15 April 2019	Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome	Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome	Plasmacytoma;POEMS Syndrome	Drug: Dexamethasone;Drug: Ixazomib Citrate;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Questionnaire Administration	Mayo Clinic	National Cancer Institute (NCI)	Recruiting	18 Years	N/A	All	34	Phase 2	United States
2	JPRN-UMIN000018660	2015/08/17	2 April 2019	Japanese POEMS syndrome with thalidmaide trial for compassionate use		Crow-Fukase(POEMS) syndrome	FPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4) Duration:until the approval of thalidomide for POEMT syndrome	Chiba University Graduate School of Medicine		Recruiting	20years-old	Not applicable	Male and Female	20	Not selected	Japan
3	JPRN-UMIN000018385	2015/07/01	2 April 2019	Phase II study of efficiency of peripheral blood stem cell harvest in POEMS syndrome patients with low-dose cyclophosphamide plus G-CSF		POEMS syndrome	This study is composed of the following two steps of therapy. 1)PBSC mobilization using low dose cyclophosphamide and G-CSF 2)autologous peripheral stem cell transplantation after high dose chemotherapy	Chiba University Hospital Department of Hematology		Not Recruiting	20years-old	70years-old	Male and Female	14	Phase 2	Japan
4	NCT02193698	July 2014	8 August 2016	Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial	Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome	POEMS Syndrome	Drug: Lenalidomide+Dexamethasone	Chiba University		Not recruiting	20 Years	N/A	Both	5	Phase 2	Japan
5	NCT01816620	March 2014	16 December 2017	Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome	An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome	POEMS Syndrome	Drug: Lenalidomide, Dexamethasone	Peking Union Medical College Hospital	Celgene Corporation	Not recruiting	18 Years	N/A	All	41	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT01639898	July 2012	15 July 2019	POEMS Syndrome Treatment With Lenalidomide	Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.	POEMS Syndrome	Drug: Lenalidomide and dexamethasone	University Hospital, Limoges	Ministry of Health, France;Celgene Corporation	Not recruiting	18 Years	N/A	All	51	Phase 2	France
7	JPRN-JMA-IIA00084	22/03/2012	2 April 2019	Japanese POEMS Syndrome with Thalidomide Trial	Japanese POEMS Syndrome with Thalidomide Trial	Crow-Fukase (POEMS) syndrome	Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL.	J-POST Clinical Trial Office	Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University	Not Recruiting	>=20 YEARS	No Limit	BOTH	24	Phase 3	Japan
8	JPRN-JMA-IIA00046	13/09/2010	2 April 2019	Japanese POEMS Syndrome with Thalidomide Trial	Thalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term Safety	Crow-Fukase (POEMS)syndrome	Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL.	J-POST Clinical Trial Office	Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University	Not Recruiting	>=20 YEARS	No Limit	BOTH	24	Phase 2-3	Japan
9	EUCTR2008-003202-33-IT	15/09/2009	19 March 2012	Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002	Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002	POEMS SYNDROME MedDRA version: 9.1 Level: SOC Classification code 10029205	Trade Name: *REVLIMID21CPS 25MG Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lenalidomide** Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-	ISTITUTO CLINICO HUMANITAS		Authorised			Female: yes Male: yes			Italy
10	NCT00971685	July 2009	19 February 2015	The Treatment of Lenalidomide in Patients With POEMS Syndrome	Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome	POEMS Syndrome	Drug: Lenalidomide and dexamethasone	Istituto Clinico Humanitas		Recruiting	18 Years	N/A	Both	16	Phase 2	Italy

先頭へ